All In Biotech

Drug Trial Radar · NCT07815665

A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

A Randomized Phase 2/3 Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Oct 31, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Summit TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

Conditions

  • Metastatic Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma (UC)

Interventions

  • Ivonescimab Dose 1Drug

    First ivonescimab dose to be tested in Phase 2

  • enfortumab vedotin (EV)Drug

    Standard of care therapy

  • PembrolizumabDrug

    200 mg

  • Ivonescimab Dose 2Drug

    Second Ivonescimab dose to be tested in Phase 2 part of the study

  • Ivonescimab RP3DDrug

    Recommended Phase 3 dose of Ivonescimab after Phase 2 data analysis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2 Primary Outcome MeasureTime frame: Through 90 days after the last study treatment
  2. Phase 2 Primary Outcome MeasureTime frame: From first dose until approximately 30 days after the last study treatment, assessed up to 3 years
  3. Phase 2 Primary Outcome measureTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years
  4. Phase 2 Primary Outcome MeasureTime frame: From first dose until end of treatment, assessed up to 3 years
  5. Phase 3 Primary Outcome MeasureTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.
  6. Phase 3 Primary Outcome MeasureTime frame: From date of randomization until the end of study, assessed up to 4 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Not yet recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Not yet recruiting

  • Research Site

    Rochester, Minnesota · Not yet recruiting

  • Research Site

    Nashville, Tennessee · Not yet recruiting

  • Research Site

    Spokane, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.